临床小儿外科杂志  2025, Vol. 24 Issue (4): 326-330  DOI: 10.3760/cma.j.cn101785-202501060-005

引用本文  

张鑫, 隋文渊. Ⅰ型神经纤维瘤病伴重度脊柱侧后凸畸形的诊治及文献复习[J]. 临床小儿外科杂志, 2025, 24(4): 326-330.   DOI: 10.3760/cma.j.cn101785-202501060-005
Zhang X, Sui WY. Diagnosis and treatment of neurofibromatosis type 1 associated with severe spinal deformity: a literature review[J]. J Clin Ped Sur, 2025, 24(4): 326-330.   DOI: 10.3760/cma.j.cn101785-202501060-005

基金项目

国家自然科学基金(82472389、82002918)

通信作者

隋文渊, Email: suiwenyuan@hotmail.com

文章历史

收稿日期:2025-02-24
Ⅰ型神经纤维瘤病伴重度脊柱侧后凸畸形的诊治及文献复习
张鑫1 , 隋文渊2     
1. 上海交通大学医学院附属新华医院儿童血液肿瘤科, 上海 200092;
2. 上海交通大学医学院附属新华医院脊柱中心, 上海 200092
摘要目的 探讨Ⅰ型神经纤维瘤病伴重度脊柱侧后凸畸形的临床特征、诊疗策略及预后。方法 回顾性分析上海交通大学医学院附属新华医院收治的1例20岁女性Ⅰ型神经纤维瘤病伴脊柱侧后凸畸形患者的临床资料,结合《Ⅰ型神经纤维瘤病临床诊疗专家共识(2021版)》的诊断标准,总结其临床表现、影像学特征及分阶段手术治疗效果。同时,以“neurofibromatosis type 1 AND spinal deformity”及“Ⅰ型神经纤维瘤病和脊柱侧后凸畸形”为关键词,检索PubMed、Web of Science数据库及万方数据库、中国知网,筛选2010—2023年符合纳入排除标准的相关文献,归纳总结诊疗要点及预后特征。结果 患者为20岁女性,自幼全身散布咖啡牛奶斑(≥6处),背部有10 cm×10 cm丛状神经纤维瘤,腋窝及腹股沟区多发皮下结节。脊柱侧后凸病程11年,影像学显示Cobb角145°,伴椎体扇形变及肋骨扭曲。双下肢肌力Ⅳ级,踝阵挛阳性。经过头颅-骨盆牵引(halo-gravity traction, HGT),Cobb角为85°,实施后路经椎弓根截骨矫形术(pedicle subtraction osteotomy, PSO)与全椎弓根螺钉固定术,术后脊柱在冠状面和矢状面上保持良好平衡。随访2年,患者症状显著改善。共纳入2010—2023年公开发表的文献5篇进行分析,涉及117例伴脊柱侧后凸畸形的Ⅰ型神经纤维瘤病患者,这些患者均具有丛状神经纤维瘤。脊柱筛查间隔尚未达成共识,手术多采用后路截骨结合椎弓根固定,而丛状神经纤维瘤常采用切除和椎板切除术。前后关节融合术对营养不良性颈椎后凸畸形的矫正效果最佳。结论 Ⅰ型神经纤维瘤病伴脊柱侧后凸畸形的治疗需遵循“牵引-截骨矫形-神经功能保护”的综合策略。PSO联合全椎弓根固定能够有效矫正畸形并维持脊柱稳定性,多学科协作与术中神经电生理监测是减少并发症的关键。
关键词Ⅰ型神经纤维瘤病    脊柱侧后凸    矫形外科手术    椎板切除术    截骨术    手术中并发症    手术后并发症    治疗结果    
Diagnosis and treatment of neurofibromatosis type 1 associated with severe spinal deformity: a literature review
Zhang Xin1 , Sui Wenyuan2     
1. Department of Pediatric Hematology/Oncology, Affiliated Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;
2. Spine Center, Affiliated Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Abstract: Objective To explore the clinical characteristics, therapeutic strategies and outcomes of children with neurofibromatosis type 1 (NF1) complicated by severe spinal deformity. Methods A retrospective analysis was conducted for the relevant clinical data of a 20-year-old female patient with neurofibromatosis type 1 (NF1) complicated by spinal deformity.Based upon the diagnostic criteria outlined in the Clinical Diagnosis and Treatment Expert Consensus on Neurofibromatosis Type 1 (Edition 2021), the authors summarized her clinical manifestations, imaging features and the effects of staged surgery.Additionally, literature searches were performed using PubMed, Web of Science, Wanfang Database and CNKI with keywords "neurofibromatosis type 1 AND spinal deformity" for screening the relevant literature from 2010 to 2023 that fulfilled some inclusion and exclusion criteria.We summarized the key points of diagnosis and treatment as well as prognostic characteristics. Results She developed multiple café-au-lait spots (≥6) since childhood, a 10 cm×10 cm plexiform neurofibroma on her back and multiple subcutaneous nodules in axillary and groin areas.Spinal deformity had a duration of 11 years with a Cobb angle of 145°, accompanied by vertebral wedging and rib deformities.Muscle strength in both lower limbs was graded at Ⅳ with positive ankle clonus.After cranial-pelvic traction (Halo-gravity Traction, HGT), Cobb angle dropped to 85°, and posterior pedicle subtraction osteotomy (PSO) plus total pedicle screw fixation was performed.Postoperatively spine maintained good balance in both coronal and sagittal planes.During a 2-year follow-up, her symptoms had significantly improved.The literature analysis included five articles (2010-2023) involving 117 patients with NF1 and spinal deformity, all presenting with plexiform neurofibromas.There is still no consensus on the interval for spinal screening.Surgery commonly involves posterior osteotomy plus pedicle fixation.Resection and laminectomy are recommended for plexiform neurofibromas.Anterior and posterior spinal fusions are effective for correcting nutritional-related cervical kyphosis. Conclusions The treatment of NF1 complicated by spinal deformity should follow a comprehensive strategy of "traction-osteotomy-neuroprotection." PSO plus total pedicle fixation effectively may correct deformity and maintain spinal stability while multidisciplinary collaboration and intraoperative neurophysiological monitoring are crucial to reducing complications.
Key words: Neurofibromatosis Type 1    Scoliosis and Kyphosis    Orthopedic Procedures    Laminectomy    Osteotomy    Intraoperative Complications    Postoperative Complications    Treatment Outcome    

Ⅰ型神经纤维瘤病(neurofibromatosis type 1, NF1)属于常染色体显性遗传病,主要在儿童期发病,10岁以下为发病高峰期,发病率约1/3 000[1]。典型临床表现为咖啡牛奶斑(Café-au-Lait Macules, CALMs)、腋窝或腹股沟雀斑、皮肤或丛状神经纤维瘤(plexiform neurofibroma, PN)、lisch结节、视神经胶质瘤和骨骼畸形[2]。30%~60% 的NF1患者会出现PN,脊柱畸形在NF1骨骼畸形中最常见,发病率2%~69%[3]。NF1伴脊柱侧弯具有发生早、进展迅速,以及侧凸合并后凸、成角的发生率高等特点。一旦进展为重度脊柱畸形,治疗将非常棘手,术后极易出现神经损伤、内固定断裂、伤口感染、内固定外露等并发症。本文报道1例NF1伴重度脊柱畸形女性患者的临床治疗过程,并结合文献探讨NF1-PN伴脊柱畸形的治疗。病例资料

一、本院患儿临床资料

患者女,20岁,因“胸背部隆起并进行性加重11年”就诊。11年前发现胸背部凸起,双肩不等高,全身皮肤大面积散在咖啡牛奶斑,腋窝、腹股沟雀斑。11年来,背部畸形进行性加重,2020年7月突发双下肢运动功能障碍,无法行走伴鞍区感觉障碍。2020年8月于外院就诊,行头颅骨盆环牵引术,术后下肢肌力逐渐恢复至可自行行走。2021年1月再发双下肢麻木、乏力,进行性加重,无法行走,伴鞍区感觉障碍,至本院就诊,行头颅-骨盆环牵引调整,后症状逐步缓解至正常行走。2021年5月,在全身麻醉下行脊柱侧后路PSO,术中出现一过性神经功能损伤诱发电位改变,术后给予营养神经等对症治疗。现术后2年余,神经功能状态同术前状态,脊柱矫形效果维持满意。

患者头颅骨盆牵引状态见图 1。步态正常,全身散在6个以上、直径>15 mm的CALMs,背部局部可见大小约10 cm×10 cm的PN,皮肤触诊背部及腋窝、腹股沟处多发皮下结节及肿块,质韧,活动度可,边界清楚,无压痛。腋窝及腹股沟区可见色素沉着。背部隆起,呈剃刀背畸形,左侧肩胛骨向后突出,双肩不等高,右肩高于左肩2 cm,双下肢感觉无明显减退,鞍区感觉减退,肌张力增高,双下肢肌张力略增高,髂腰肌、股四头肌、胫前肌、踇长伸肌、足背肌、内收肌及外展肌力Ⅳ级,双侧踝阵挛阳性,双侧膝反射及踝反射亢进,双侧Babinski征阳性,双下肢足背动脉搏动正常、对称。


图 1 Ⅰ型神经纤维瘤病患者头颅-骨盆牵引手术治疗过程照片 Fig.1 Photos of craniopelvic traction surgical process in a child with craniopelvic neurofibromatosis type 1   A: 牵引后患者背部显示,黄色箭头指丛状神经纤维瘤;B: 牵引后侧面视图显示脊柱侧弯;C: 牵引后正面外观

X线检查提示:头颅环牵引状态,脊柱侧后凸畸形,冠状面失衡,肋骨细长,椎间孔扩张,肋骨细长,椎体及附件结构紊乱。CT检查提示:脊柱侧后凸畸形,椎板部分破坏、缺如,椎体扇贝样改变,皮质骨破坏缺损,椎弓根硬化细长,椎管扩张,神经根管扩大。部分肋椎关节脱位(图 2)。MRI检查提示:脊柱侧后凸畸形,脊膜扩大,椎管内膨出,椎板细薄,皮质骨破坏,局部缺如,椎弓根细长,神经根管扩大,椎旁有神经纤维瘤侵犯(图 3)。


图 2 Ⅰ型神经纤维瘤病患者脊柱CT及三维重建 Fig.2 CT images and 3D imaging of spine in a child with neurofibromatosis type 1   A:Ⅰ型神经纤维瘤病患者脊柱CT;B、C:CT三维重建影像显示脊柱侧弯伴后凸畸形及骨质破坏


图 3 Ⅰ型神经纤维瘤病患者典型脊柱MRI改变 Fig.3 Typical spinal MRI changes in a child with neurofibromatosis type 1   A、B提示脊柱侧后凸畸形;C、D提示脊膜扩大、椎管内膨出、椎板细薄及局部缺失,椎旁伴有神经纤维瘤侵犯

根据《1型神经纤维瘤病临床诊疗专家共识(2021版)》,NF1主要依赖于临床诊断,国际神经纤维瘤病诊断标准共识组(International Neurofibromatosis Diagnostic Criteria Consensus Group, I-NF-DC)对1987年制定的NF1诊断标准提出了修正建议,主要加入了基因学诊断。本例符合Ⅰ型神经纤维瘤病临床诊断标准,且伴有脊柱侧后凸畸形,畸形的病变特点与神经纤维瘤病引起的脊柱改变完全相符。

患者入院后完善相关辅助检查(心脏超声、肺功能、心电图、心脏大血管造影、肺部CT等),经本院多学科会诊,排除手术绝对禁忌证,于全身麻醉下行脊柱侧后凸畸形截骨矫正术。术中在全程多模式诱发电位监护下,行双侧第1胸椎至第4腰椎椎弓根螺钉置入,并通过第7、8胸椎实施全脊柱切除术(vertebral column resection, VCR)及双侧固定棒矫形。术中神经监测方法包括:①双侧胫后神经诱发电位(cortical somatosensory evoked potentials, CSEP);②双侧正中神经CSEP;③双侧鱼际肌、上腹直肌、股内收肌、股四头肌、腘窝、胫前肌、足底肌经颅电刺激运动诱发电位(从上至下排列)(transcranial electrical stimulation motor evoked potentials, TES-MEP);④直接神经电位(direct nerve electrical potentials,DNEP);⑤四个成本刺激(train of four, TOF);⑥功能性肌电图(functional electromyography, f-EMG);⑦脑电图(electroencephalography, EEG)。

患者术后3 d佩戴支具下地行走,神经功能检查双下肢感觉无明显减退,但鞍区感觉减退,肌张力增高。双下肢肌张力略有增加,髂腰肌、股四头肌、胫前肌、踇背伸肌、内收肌及外展肌的力量均评定为Ⅳ级。双侧踝阵挛阳性,双侧膝反射及踝反射亢进,双侧Babinski征阳性,双下肢足背动脉搏动正常、对称,与术前一致。术后1周复查X线片冠状面及矢状面均获得满意矫形效果,外观明显改善(图 4)。考虑到PN持续对脊柱椎体造成压迫,远期内固定失败的风险较高,故在手术中进行了大量自体及异体骨植骨,并采用卫星棒技术进行截骨稳定。术后随访两年余,临床效果满意。


图 4 Ⅰ型神经纤维瘤病患者术前与术后X线影像对比 Fig.4 Comparison of preoperative and postoperative X-ray imaging in a child with neurofibromatosis type 1   A:Ⅰ型神经纤维瘤病患者术前X线正位片,显示脊柱侧弯情况;B:术前侧位片,可观察脊柱后凸及整体形态;C、D:术后正位和侧位影像,脊柱外观得到显著矫正,内固定装置位置良好
二、文献检索情况

检索中国知网、万方医学网、PubMed、Web of Science等数据库。中文检索词为Ⅰ型神经纤维瘤病和脊柱侧后凸畸形,英文检索词为neurofibromatosis type 1 AND spinal deformity或NF1 AND scoliosis。检索日期为2010年1月1日至2023年12月31日。文献纳入标准:①关于Ⅰ型神经纤维瘤病和脊柱侧后凸畸形的个案报道或病例报道;②年龄小于18岁。排除标准:仅在文章摘要描述、信息缺失过多或笼统描述病例数而无具体临床资料的文献。

共纳入5篇符合纳排标准的文献,报道117例NF1-PN伴脊柱侧后凸畸形患者。脊柱筛查间隔无共识。丛状神经纤维瘤最常采用切除和椎板切除术治疗。丝裂原活化蛋白激酶激酶(mitogen-activated protein kinase kinase, MEK) 抑制剂对缩小肿瘤效果有限。雷帕霉素和沙利度胺能够减少肿瘤体积,但其不良反应较MEK抑制剂更严重。前后关节融合术对营养不良性颈椎后凸畸形的矫正效果最佳(表 1)。

表 1 2010—2023年文献报道丛状神经纤维瘤伴脊柱侧弯患儿病例资料 Table 1 Case records of children with plexiform neurofibromas associated with scoliosis reported since 2010-2023
讨论

NF1是一种由17q染色体上NF1基因突变引起的多系统疾病,其编码的神经纤维蛋白通过调控RAS-MAPK通路参与细胞分化与生长抑制,突变可导致神经、骨骼及软组织病变[9]。骨骼系统受累表现为脊柱畸形(10%~20%)、先天性胫骨弯曲及肢体过度生长等,其中脊柱侧凸最为常见,约2%的脊柱侧凸患者合并NF1[9-11]。根据椎体结构特征,NF1脊柱侧凸分为营养不良性(椎体扇形变、肋骨铅笔样改变)和非营养不良性,前者具有进展快(年Cobb角增加达23°)、手术风险高的特点[9, 12]

研究表明,75%的NF1患者存在脊柱后凸,伴严重椎体扇贝样改变者年进展速度显著高于无此特征者(23°比7°)[12]。即使行内固定融合术,椎体半脱位、椎间盘楔形变及外周骨骼营养不良仍可导致术后畸形进展,侧后凸>50°或累及≥3个椎体的角状后凸畸形平均进展达38°[3]。非营养不良性患者治疗原则与特发性脊柱侧凸相似(支具治疗阈值20°~35°,手术阈值>35°),而营养不良性患者因支具控制率<20%,即使Cobb角在20°也需要手术干预[13]。对于Cobb角>50°的重度畸形,前后路联合融合可使假关节发生率从单纯后路的63%降至20%,但需警惕后凸进展引发肋骨头突入椎管导致截瘫的风险[14]

本例为典型重度营养不良性脊柱侧后凸畸形,椎管内外瘤体侵袭与椎体广泛破坏加速了畸形进展。针对此类高难度手术,主要目的在于阻止畸形进展,获得满意的冠状面和矢状面平衡,缩短手术时间,减少异体输血,降低神经并发症的发生率。本中心采用分阶段治疗策略:一期头颅骨盆环牵引(halo-pelvic traction,HPT)通过菱形分布4枚半钉(间距>3 cm)联合每日≤4 mm的间歇牵引,使胸廓容积增加、降低Cobb角,同时采用分散髂骨螺钉分布策略以减少牵引相关并发症;二期O-arm导航辅助置钉(准确率98.6%)、次顶椎区域截骨(第10胸椎节段35°楔形截骨)及多模式神经监护,进一步减少神经并发症的发生,自体血回输联合使用氨甲环酸使术中出血量降至1 800 mL(较传统术式减少40%)。术后6个月CT复查显示截骨区骨融合率达91.3%,证实骨形态发生蛋白2(bone morphogenetic protein 2,BMP-2)强化植骨的有效性。

近年来,MEK抑制剂Selumetinib为NF1合并PN的治疗提供了新方向。该药物通过抑制RAS-MAPK通路,能够显著缩小PN的体积,在SPRINT试验中,约67%的患者肿瘤缩小≥20%。此外,Selumetinib可能通过上调Runx2的表达来改善骨代谢[15]。本中心研究显示,中国儿童患者使用Selumetinib(25 mg/m2,每日2次) 后约75%的患者目标瘤体体积缩小,疼痛与功能评分显著改善,3级以上不良事件的发生率仅6.3%,未发生与药物相关的严重不良反应(severe adverse reactions, SAE),与SPRINT试验数据一致[16]。有研究评估了MEK抑制剂Selumetinib对NF1患者脊柱神经纤维瘤(Spinal neurofibromas,SNF)的疗效,结果显示18例患者在影像学上SNF负担有所改善,5例保持稳定,未出现病情恶化。Selumetinib可能通过预防脊髓压迫的加重,从而减少部分患者对手术的需求,特别是对于无法手术的患者具有潜在益处[17]

基于现有证据,我们提出阶梯式干预路径:①Cobb角<30°者采用Selumetinib联合3D打印动态支具;②Cobb角30°~50°者行短节段选择性融合;③Cobb角>50°者采取360°融合联合BMP植骨。

利益冲突  所有作者声明不存在利益冲突

作者贡献声明  隋文渊负责论文设计; 隋文渊、张鑫负责数据收集、文献检索、研究结果分析与讨论、论文撰写及全文知识性内容的审读与修正

参考文献
[1]
Lee TSJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2:a systematic review and meta-analysis[J]. Orphanet J Rare Dis, 2023, 18(1): 292. DOI:10.1186/s13023-023-02911-2
[2]
Zhu BY, Zheng TT, Wang W, et al. Genotype-phenotype correlations of neurofibromatosis type 1:a cross-sectional study from a large Chinese cohort[J]. J Neurol, 2024, 271(4): 1893-1900. DOI:10.1007/s00415-023-12127-w
[3]
Toro G, Santoro C, Ambrosio D, et al. Natural history of scoliosis in children with NF1:an observation study[J]. Healthcare (Basel), 2021, 9(7): 881. DOI:10.3390/healthcare9070881
[4]
Suresh KV, Xu AL, Groves ML, et al. Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1:a systematic review[J]. J Pediatr Orthop B, 2022, 31(6): 572-582. DOI:10.1097/BPB.0000000000000961
[5]
Habeshian K, Saadeh-Haddad R, DeKlotz C. Plexiform neurofibromas in twins with neurofibromatosis type 1[J]. J Am Acad Dermatol, 2017, 76(6, Supplement): AB200. DOI:10.1016/j.jaad.2017.04.779
[6]
Hu ZS, Liu Z, Qiu Y, et al. Morphological differences in the vertebrae of scoliosis secondary to neurofibromatosis type 1 with and without paraspinal neurofibromas[J]. Spine (Phila Pa 1976), 2016, 41(7): 598-602. DOI:10.1097/BRS.0000000000001455
[7]
Nguyen R, Dombi E, Akshintala S, et al. Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging[J]. J Neurooncol, 2015, 121(1): 209-215. DOI:10.1007/s11060-014-1629-5
[8]
杨阳, 王升儒, 林莞锋, 等. 一期单纯后路矫形融合治疗Ⅰ型神经纤维瘤病伴营养不良型脊柱侧后凸1例报道[J]. 中华骨与关节外科杂志, 2019, 12(4): 298-303.
Yang Y, Wang SR, Lin WF, et al. One-stage posterior-only approach for dystrophic scoliosis secondary to neurofibromatosis typeⅠ[J]. Chin JBone Joint Surg, 2019, 12(4): 298-303. DOI:10.3969/j.issn.2095-9958.2019.04.013
[9]
Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis[J]. Int J Mol Sci, 2021, 22(11): 5850. DOI:10.3390/ijms22115850
[10]
祁新禹, 张学军, 白云松, 等. 凸侧短段固定凹侧生长棒技术治疗小儿神经纤维瘤病脊柱侧弯[J]. 临床小儿外科杂志, 2015, 14(4): 271-274.
Qi XY, Zhang XJ, Bai YS, et al. Treating scoliosis caused by neurofibromatosis with brief fixing on convex side combined with growing rod on concave side[J]. J Clin Ped Sur, 2015, 14(4): 271-274. DOI:10.3969/j.issn.1671-6353.2015.04.005
[11]
Mao SH, Li S, Ma YY, et al. How to rectify the convex coronal imbalance in patients with unstable dystrophic scoliosis secondary to type Ⅰ neurofibromatosis: experience from a case series[J]. BMC Musculoskelet Disord, 2022, 23(1): 368. DOI:10.1186/s12891-022-05321-w
[12]
Tsirikos AI, Dhokia R, Wordie S. Rotatory dislocation of the spine in dystrophic kyphoscoliosis secondary to neurofibromatosis type 1[J]. J Cent Nerv Syst Dis, 2018, 10: 1179573518819484. DOI:10.1177/1179573518819484
[13]
Moodley M, Lopez KR. Neurofibromatosis type 1-an update[J]. Semin Pediatr Neurol, 2024, 52: 101172. DOI:10.1016/j.spen.2024.101172
[14]
Shao XX, Huang ZF, Yang JF, et al. Efficacy and safety for combination of t-EMG with O-arm assisted pedicle screw placement in neurofibromatosis type Ⅰ scoliosis surgery[J]. J Orthop Surg Res, 2021, 16(1): 731. DOI:10.1186/s13018-021-02882-9
[15]
Park BJ, Hyun SJ, Wui SH, et al. Surgical outcomes and complications following all posterior approach for spinal deformity associated with neurofibromatosis type-1[J]. J Korean Neurosurg Soc, 2020, 63(6): 738-746. DOI:10.3340/jkns.2019.0218
[16]
Wang ZC, Zhang X, Li CY, et al. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: the primary analysis of a phase 1 open-label study[J]. Clin Transl Med, 2024, 14(3): e1589. DOI:10.1002/ctm2.1589
[17]
Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas[J]. Neurooncol Adv, 2020, 2(1): vdaa095. DOI:10.1093/noajnl/vdaa095